Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing - Top-Institutions - MDSpire

Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing

  • By

  • Shucheng Zhang

  • Zhuqing Li

  • Yang Lin

  • Xiaoyue Sun

  • Meng Qiao

  • Xiaoqing Si

  • May 26, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The First Affiliated Hospital of Shandong First Medical University
    The First Affiliated Hospital of Shandong First Medical University

    Jinan, Shandong

    Key Differentiators

    • Dermatology

  • #2

    Heze Municipal Hospital
    Heze Municipal Hospital

    Heze, Shandong

    Key Differentiators

    • Dermatology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Dermatology

  • #4

    Stanford University
    Stanford University

    Stanford, California

    Key Differentiators

    • Dermatology
    • Pathology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Dermatology

Original Source(s)

Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing

  • by Shucheng Zhang, Zhuqing Li, Yang Lin, Xiaoyue Sun, Meng Qiao, Xiaoqing Si

  • May 26, 2026

Related Content

Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health

Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...

2026 NCCN Clinical Practice Guidelines in Oncology®: Key Updates Across Tumor Types

The National Comprehensive Cancer Network® (NCCN®) first introduced the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, initially covering eight tumor types. Three decades la...

Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...